8-K: QT Imaging Reports Strong Q2 Growth, Raises $10M

QT Imaging announced robust second-quarter financial results, with revenue soaring to $7.4 million, driven by increased scanner shipments and a successful $10 million public offering.

Summary

• QT Imaging reported a significant increase in second-quarter revenue, reaching $7.4 million, a 103% rise year-over-year.
• For the first six months of 2026, revenue grew 116% to $14.0 million.
• The company shipped 15 Breast Acoustic CT scanners in Q2 2026, up from 8 in Q2 2025.
• A $10.0 million public offering was completed to strengthen the capital position.
• Full-year 2026 revenue guidance is reaffirmed at approximately $39 million.
• The company received regulatory authorization in Israel and Saudi Arabia.
• A routine FDA inspection was completed with zero Form 483 observations.
• Manufacturing capacity was expanded with a new 22,000-square-foot facility.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, highlighting significant revenue growth, successful capital raise, and strategic expansion, with strong reaffirmation of future guidance.

Positives

• Revenue more than doubled year-over-year to $7.4 million in the second quarter of 2026.
• First-half revenue increased 116% to $14.0 million.
• Fifteen Breast Acoustic CT scanners were shipped in Q2 2026, compared to eight in the prior-year period.
• Successfully completed a $10.0 million public offering, strengthening the capital position.
• Extended the maturity of its senior secured term loan by two years.
• Received regulatory authorization in Israel (AMAR) and Saudi Arabia.
• Completed its first routine FDA inspection with zero Form 483 observations.
• Demonstrated less than 1% variability in Speed of Sound measurements across scanners in a multi-site study.
• Expanded manufacturing capacity to a new 22,000-square-foot facility, improving operating efficiency and reducing lease cost per square foot by approximately 55%.
• Added to the Russell Microcap Index.

Negatives

• Gross margin decreased to 41% in Q2 2026 from 50% in Q2 2025, attributed to a higher weighted average cost of inventory sold.
• Total operating expenses increased to $4.9 million in Q2 2026 from $2.9 million in Q2 2025, primarily due to higher employee compensation, professional services, and marketing expenses.
• Operating loss increased to $1.9 million in Q2 2026 from $1.0 million in Q2 2025.
• Total interest and other expense, net, significantly increased to $9.2 million in Q2 2026 from $3.0 million in Q2 2025, largely due to an $8.3 million non-cash loss on debt extinguishment related to the Lynrock Lake term loan modification.
• Net loss widened to $11.1 million ($0.75 per share) in Q2 2026 from $4.0 million ($0.42 per share) in Q2 2025.
• Non-GAAP adjusted EBITDA was negative $1.2 million in Q2 2026, compared to negative $0.8 million in Q2 2025.
• Net cash used in operating activities increased to $4.8 million in Q2 2026 from $1.4 million in Q2 2025.

Risks

• The company may never be able to effectuate its business plan or achieve meaningful revenue or reach profitability.
• The QTI Breast Acoustic CT Scanner and other products in development may not achieve widespread market acceptance.
• Additional capital may be needed, which may not be available on favorable terms, potentially causing dilution or restricting operations.
• The ability to generate sufficient cash to pay debt obligations and refinance indebtedness depends on factors beyond the company's control.
• Debt agreements contain restrictions that may limit operational flexibility.
• Geopolitical developments have impacted commercial activities in parts of the Gulf region.
• The company faces competition in the medical imaging market.
• There is a material weakness in internal controls over financial reporting.

Future Outlook

The company reaffirms its full-year 2026 revenue guidance of approximately $39 million, based on minimum order quantities from distribution agreements and expected contributions from direct sales efforts.

Management Comments

• "Our second quarter results demonstrate continued execution and the growing commercial momentum of QT Imaging."
• "Revenue more than doubled year-over-year to $7.4 million, and we shipped fifteen Breast Acoustic CT scanners during the quarter, compared with eight in the prior-year period."
• "We also took important steps to support continued growth, completing a $10 million public offering, expanding our direct U.S. sales organization, and securing regulatory authorization in Israel and Saudi Arabia."
• "These are tangible steps toward scaling Breast Acoustic CT commercially while building the clinical, regulatory and operational foundation for broader adoption."
• "With more than 12,000 women already imaged using our technology, we are building more than an innovative medical imaging system; we are building a quantitative breast imaging platform that integrates advanced hardware, software, cloud infrastructure and, over time, AI-enabled clinical applications."
• "At the same time, we continue to evolve our commercial strategy by complementing our established distribution partnerships with expanded direct commercial, and business development capabilities to accelerate customer engagement and broaden adoption."

Industry Context

StockSavvy.ai notes that QT Imaging's focus on radiation-free, non-compression breast imaging aligns with industry trends towards personalized medicine, precision diagnostics, and AI integration in radiology. The company's progress in securing regulatory approvals in new international markets and its expansion of direct sales capabilities are key strategic moves in the competitive medical device landscape.

Comparison to Industry Standards

• The company's multi-site repeatability and reproducibility study demonstrated less than 1% variability in Speed of Sound measurements, which is significantly lower than the 11-22% variability reported for published breast MRI biomarkers (QIBA ADC benchmark).
• QT Imaging aims to offer a comparable detection profile to MRI for high-risk women, as suggested by a Mayo Clinic feasibility study.
• The company's revenue growth of 103% year-over-year in Q2 2026 is a strong indicator of market traction, though direct comparisons to specific competitors' quarterly results are not provided in this filing.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth, successful capital raise, and reaffirmed guidance, offset by increased operating expenses and net loss. Dilution risk if further capital is raised.
• Employees: Expansion of direct commercial organization with new VP appointments suggests potential for job growth and increased compensation costs.
• Customers/Clinicians: Continued development of technology and expanded regulatory approvals offer advanced diagnostic tools. Improved patient experience with radiation-free, non-compression imaging.
• Suppliers: Increased manufacturing capacity may lead to higher demand for raw materials and components.

Next Steps

• Continue to pursue commercial opportunities through distribution partners and expanded internal commercial capabilities.
• Pursue additional regulatory authorizations in the Gulf region and Europe.
• Advance clinical expansion in Israel with the first scanner placement at Rambam Health Care Campus for a clinical study.
• Continue development activities including enhancements to image reconstruction, quantitative imaging algorithms, clinical workflow, and the QTI Precision Pathway cloud platform.
• Continue collaboration with Olea Medical to productize its multimodality image viewer, physician workflow, and quantitative image analysis.
• Focus on scaling production efficiently in the new manufacturing facility.
• Engage in grassroots initiatives focused on breast health awareness.

Key Dates

Recommendation

The company shows strong revenue growth and strategic progress, including a successful capital raise and international expansion. However, the widening net loss, increased operating expenses, and significant debt extinguishment loss warrant a cautious approach. While the outlook is positive, the path to profitability remains a key concern, suggesting a 'hold' position until sustained profitability is demonstrated.

Keywords

Breast Acoustic CT, medical device, breast health, imaging technology, revenue growth, FDA clearance, regulatory authorization, financial results